The biopharmaceutical industry has been extremely generous toward investors over the last eight years. Since Jan. 1, 2010, for example, this high-flying industry has absolutely crushed the broader markets. The chart below outlining the performance of the iShares Nasdaq Biotechnology ETF vs. the SPDR S&P 500 ETF over this particular time period illustrates this point perfectly:IBB data by YCharts.Continue reading